Cutter & CO Brokerage Inc. Increases Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Cutter & CO Brokerage Inc. boosted its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 69.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,135 shares of the biotechnology company’s stock after acquiring an additional 13,600 shares during the period. Cutter & CO Brokerage Inc.’s holdings in Heron Therapeutics were worth $51,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in HRTX. Clearline Capital LP boosted its position in Heron Therapeutics by 48.9% during the 3rd quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock valued at $4,431,000 after acquiring an additional 731,246 shares in the last quarter. Congress Park Capital LLC raised its position in shares of Heron Therapeutics by 24.1% in the 4th quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company’s stock worth $3,757,000 after acquiring an additional 477,417 shares in the last quarter. XTX Topco Ltd lifted its stake in shares of Heron Therapeutics by 449.0% in the 3rd quarter. XTX Topco Ltd now owns 297,568 shares of the biotechnology company’s stock valued at $592,000 after purchasing an additional 243,363 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Heron Therapeutics by 295.8% during the third quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company’s stock valued at $411,000 after purchasing an additional 154,487 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in Heron Therapeutics by 50.4% in the third quarter. BNP Paribas Financial Markets now owns 275,946 shares of the biotechnology company’s stock worth $549,000 after purchasing an additional 92,425 shares during the period. 80.01% of the stock is owned by hedge funds and other institutional investors.

Heron Therapeutics Stock Up 1.8 %

Shares of HRTX stock opened at $1.71 on Thursday. The company has a 50 day moving average price of $1.66 and a 200-day moving average price of $1.71. Heron Therapeutics, Inc. has a 52 week low of $1.04 and a 52 week high of $3.93. The firm has a market capitalization of $260.08 million, a PE ratio of -9.50 and a beta of 1.60.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on HRTX shares. StockNews.com cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 29th. Needham & Company LLC reissued a “buy” rating and set a $4.00 price target on shares of Heron Therapeutics in a research report on Wednesday, December 4th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.